Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

ng statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.____________________________(1) Rossignol JF. Thiazolides: A new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009;5:667-674.(2) Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide, and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir Res. 2008;77:56-63.(3) Korba BE, Elazar M, Lui P, et al. Studies of the potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52:4069-4071.(4) Yon C, Viswanathan P, Rossignol JF, Korba BE. Resistance to nitazoxanide is associated with alterations in the host and not the virus in HCV replicon-containing cultures. Submitted for publication.(5) Korba BE, Elazar M, Liu P, et al. Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance. Hepatology. 2008;48(suppl):356A.(6) Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008;28:574-580.(7) Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in patients with chronic hepatitis C genotype 4 treated with nitazoxanide plus peginterferon alfa-2a with or with
'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
(Date:4/17/2014)... ward off depression among retirees, particularly among those who ... The Journals of Gerontology, Series B: Psychological Sciences ... Internet Use and Depression Among Retired Older Adults in ... report that Internet use reduced the probability of a ... , Late-life depression affects between 5 and 10 ...
(Date:4/17/2014)... general blood flow and alleviates muscle soreness after ... the University of Illinois at Chicago. , The ... the Archives of Physical Medicine and Rehabilitation ... in people who had not exercised, suggesting that ... level of physical activity. , Improved circulation and ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... HILL In 2006, University of North Carolina at Chapel ... levels of LDL cholesterol are more likely to have Parkinson,s ... study could not answer the question of whether low LDL ... were diagnosed with Parkinsons, or if they developed low LDL ...
... Program Will Put Home Medical Equipment Providers out of,Business ... Million Seniors and,Disabled People in Kansas City Area, ... program for durable medical equipment (DME) scheduled to be,implemented ... 1,2008, will put many DME providers out of business ...
... April 4, 2008 Most people assume,that cancer is ... Cancer Society, healthy behaviors could prevent approximately half,of cancer ... all based on the,latest research, which people can make ... at its earliest, most curable stages., -- Don,t ...
... they might want to avoid theft of Social Security checks ... finds that senior citizens in Baltimore seem to avoid visiting ... because they want to stay home and make sure no ... help doctors get a better handle on fluctuations in when ...
... April 4, 2008 -- A promising vaccine being tested ... do -- clear beta-amyloid plaques from the brain -- ... learning and memory abilities, according to a University of ... the predominant pathology of Alzheimer,s disease -- beta-amyloid plaques ...
... ward off gastroenteritis, which causes vomiting and diarrhea in children ... and Drug Administration has approved a second oral vaccine for ... diarrhea in infants and children. , The Rotarix vaccine is ... from 6 to 24 weeks of age. , ...
Cached Medicine News:Health News:Pieces coming together in Parkinson's, cholesterol puzzle 2Health News:Medicare Bidding Program in Kansas City is Plagued by Problems, Says American Association for Homecare 2Health News:Medicare Bidding Program in Kansas City is Plagued by Problems, Says American Association for Homecare 3Health News:Ten Things You Can Do to Reduce Your Cancer Risk 2Health News:Ten Things You Can Do to Reduce Your Cancer Risk 3Health News:Ten Things You Can Do to Reduce Your Cancer Risk 4Health News:Ten Things You Can Do to Reduce Your Cancer Risk 5Health News:Seniors Avoid ER at Start of Month 2Health News:Seniors Avoid ER at Start of Month 3Health News:Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment 2Health News:FDA OKs New Rotavirus Vaccine 2Health News:FDA OKs New Rotavirus Vaccine 3
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
20 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Sharp tip with cutting edge bent to 50 degrees fits 19 gauge or 20 gauge instrument port, 20 gauge instrument port, 20 gauge x 25 mm tapering to 25 gauge x 4.76 mm. 10 per box....
Angled, 20 gauge x 25 mm cannula with 30 gauge x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub, angled 45 degrees 2.5 mm from tip. 10 per box....
Medicine Products: